[Katarjian's prognostic model in prognosing chronic myelogenous leukemia at diagnosis and after one year of disease duration].
We estimated survival time of 56 patients with chronic myelogenous leukemia retrospectively classified according to the model by Kantarjian. Moreover we analysed if there was a correlation between the first-year total dose of busulphan and the size of the spleen during the first year of treatment on the one hand and the patients' survival on the other and if the above factors could enhance the prognostic value of the model by Kantarjian. Although we found such a correlation our preliminary results suggest that the first-year total dose of busulphan and the spleen size do not enhance the prognostic value of the model by Kantarjian.
Kliniki Hematologii IChW i Katedry Fizjologii AM, Gdańsku.
J M
JM
Zaucha
J
J
Kaczmarek
A
A
Hellmann
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate